» Articles » PMID: 18691663

Paradigm Shifts in the Cell Biology of STAT Signaling

Overview
Date 2008 Aug 12
PMID 18691663
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

In recent years several of the key tenets of the original cytokine-STAT-signaling paradigm had to be revised. First, the notion that nonphosphorylated "inactive" STATs are present in the cytoplasm as free monomers which dimerized only subsequent to Tyr-phosphorylation has been replaced by the understanding that nonphosphorylated STATs in the cytoplasm exist largely as dimers and high molecular mass "statosome" complexes. Second, the notion that phosphorylation, either of Tyr or Ser residues or both, in STAT species is required for transcriptional activation has been replaced by the realization that nonphosphorylated STATs can be transcriptionally active albeit with respect to sets of target genes distinct from phosphorylated STATs. Third, the notion that it is the activation by phosphorylation of STATs at the plasma membrane that then leads to their import into the nucleus has been replaced by the recognition that even nonphosphorylated STATs shuttle between the cytoplasm and nucleus at all times in a constitutive manner. Fourth, the notion that the trans-cytoplasmic transit of STATs from the plasma membrane to the nuclear import machinery takes place exclusively as a free cytosolic process has been replaced by the understanding that at least a portion of this trans-cytoplasmic transit is mediated via membrane-associated caveolar and endocytic trafficking (the "signaling endosome" hypothesis). Fifth, the targeting and sequestration of activated STAT3 to long-lived endosomes in the cytoplasm requires consideration of STAT3-mediated "signal transduction" from the plasma membrane to cytoplasmic membrane destinations potentially for function(s) in the cytoplasm. Indeed, in tissue sections many discrete histologic cell types display PY-STAT3 almost exclusively in the cytoplasm with little, if any, in the nucleus. New challenges include determining the structural bases for the recruitment of nonphosphorylated dimeric STAT species to the cytosolic face of membranes including at the cytoplasmic tails of respective receptor complexes, the conformational changes subsequent to phosphorylation and the structural bases for the targeting and functions of STAT proteins within the cytoplasm per se.

Citing Articles

Chemotherapeutic Potential of Saikosaponin D: Experimental Evidence.

Manoharan S, Deivendran B, Perumal E J Xenobiot. 2022; 12(4):378-405.

PMID: 36547471 PMC: 9782205. DOI: 10.3390/jox12040027.


Screening of potent STAT3-SH2 domain inhibitors from JAK/STAT compound library through molecular dynamics simulation.

Manoharan S, Balakrishnan A, Hemamalini V, Perumal E Mol Divers. 2022; 27(3):1297-1308.

PMID: 35831728 DOI: 10.1007/s11030-022-10490-w.


Evaluation of pregnancy-associated plasma protein-A and some inflammation markers for atherosclerosis in psoriasis patients.

Akyurek F, Tuncez Akyurek F Postepy Dermatol Alergol. 2021; 38(2):151-155.

PMID: 34408582 PMC: 8362789. DOI: 10.5114/ada.2021.104290.


A Novel Gene Fusion in Solitary Fibrous Tumor: A Case Report.

Moura D, Diaz-Martin J, Bague S, Orellana-Fernandez R, Sebio A, Mondaza-Hernandez J Int J Mol Sci. 2021; 22(14).

PMID: 34299133 PMC: 8305824. DOI: 10.3390/ijms22147514.


The Dynamic Interface of Viruses with STATs.

Harrison A, Moseley G J Virol. 2020; 94(22).

PMID: 32847860 PMC: 7592203. DOI: 10.1128/JVI.00856-20.


References
1.
Subramaniam P, Johnson H . Lipid microdomains are required sites for the selective endocytosis and nuclear translocation of IFN-gamma, its receptor chain IFN-gamma receptor-1, and the phosphorylation and nuclear translocation of STAT1alpha. J Immunol. 2002; 169(4):1959-69. DOI: 10.4049/jimmunol.169.4.1959. View

2.
Reich N, Liu L . Tracking STAT nuclear traffic. Nat Rev Immunol. 2006; 6(8):602-12. DOI: 10.1038/nri1885. View

3.
Gao S, Mark K, Leslie K, Pao W, Motoi N, Gerald W . Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest. 2007; 117(12):3846-56. PMC: 2096430. DOI: 10.1172/JCI31871. View

4.
Leof E . Growth factor receptor signalling: location, location, location. Trends Cell Biol. 2000; 10(8):343-8. DOI: 10.1016/s0962-8924(00)01795-5. View

5.
Levy D, Kessler D, Pine R, Darnell Jr J . Cytoplasmic activation of ISGF3, the positive regulator of interferon-alpha-stimulated transcription, reconstituted in vitro. Genes Dev. 1989; 3(9):1362-71. DOI: 10.1101/gad.3.9.1362. View